A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2-Reference-Cited by-全球学者库

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Published:2020-06-12 Issue:6496 Volume:368 Page:1274-1278
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Wu Yan¹²^ORCID,Wang Feiran³⁴^ORCID,Shen Chenguang³⁵^ORCID,Peng Weiyu³⁶^ORCID,Li Delin³⁵⁷^ORCID,Zhao Cheng³⁸^ORCID,Li Zhaohui³⁹^ORCID,Li Shihua³^ORCID,Bi Yuhai³¹⁰^ORCID,Yang Yang⁵,Gong Yuhuan³¹⁰,Xiao Haixia⁷,Fan Zheng³,Tan Shuguang³,Wu Guizhen¹¹^ORCID,Tan Wenjie¹¹^ORCID,Lu Xuancheng¹²,Fan Changfa¹³^ORCID,Wang Qihui³,Liu Yingxia⁵,Zhang Chen¹,Qi Jianxun³,Gao George Fu³^ORCID,Gao Feng⁷^ORCID,Liu Lei⁵^ORCID

Affiliation:

1. Department of Pathogen Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.

2. Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China.

3. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.

4. School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, China.

5. Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People’s Hospital, Shenzhen, China.

6. College of Veterinary Medicine, China Agricultural University, Beijing, China.

7. Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences (CAS), Tianjin, China.

8. Shanxi Academy of Advanced Research and Innovation, Taiyuan, China.

9. University of Chinese Academy of Sciences, Beijing, China.

10. Center for Influenza Research and Early Warning, Chinese Academy of Sciences (CASCIRE), Beijing, China.

11. NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

12. Laboratory Animal Center, Chinese Center for Disease Control and Prevention, Beijing, China.

13. Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, Beijing, China.

Abstract

An antibody defense against COVID-19 One of the responses of the immune system to invading viruses is the production of antibodies. Some of these are neutralizing, meaning that they prevent the virus from being infectious, and can thus be used to treat viral diseases. Wu et al. isolated four neutralizing antibodies from a convalescent coronavirus disease 2019 (COVID-19) patient. Two of the antibodies, B38 and H4, blocked the receptor binding domain (RBD) of the viral spike protein from binding to the cellular receptor, angiotensin-converting enzyme 2 (ACE2). The structure of the RBD bound to B38 shows that the B38-binding site overlaps with the binding site for ACE2. Although H4 also blocks RBD binding to ACE2, it binds at a different site, and thus the two antibodies can bind simultaneously. This pair of antibodies could potentially be used together in clinical applications. Science , this issue p. 1274

Funder

Ministry of Science and Technology

National Natural Science Foundation of China

Zhejiang University

the National Key R&D Program of China

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference22 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. A novel coronavirus outbreak of global health concern